Synopsis

Keywords: Body: Pelvis

For ovarian cancer diagnosis, the O-RADS MRI score allows characterising the lesion as benign, borderline or malignant with very high predictive values. Though O-RADS itself does not integrate quantitation, quantitative imaging played a major role in establishing evidence, and more specifically developing the visual enhancement curves. At the (mostly peritoneal) metastatic stage, diffusion-weighted sequences have been used for detection and quantification of the Peritoneal Cancer Index, a predictor of resectability and survival. Finally, conventional imaging does not currently predict or monitor treatment response or recurrence, and more advanced quantitative techniques such as radiomics may supply some of the answers.

Imaging plays a role at three stages of ovarian cancer. At the diagnostic stage, the O-RADS MRI score allows characterising the ovarian lesion as benign, borderline or malignant with very high predictive values. Though O-RADS itself does not integrate quantitation, quantitative imaging has played a major role in establishing the evidence and criteria, and more specifically developing the visual enhancement curves. At the (mostly peritoneal) metastatic stage, diffusion-weighted sequences have been used for detection and quantification of the Peritoneal Cancer Index, a predictor of resectability and survival. Finally, conventional imaging does not currently predict or monitor treatment response or recurrence, and more advanced quantitative techniques such as radiomics may supply some of the answers.

SUMMARY OF MAIN FINDINGS

Quantitative imaging has helped develop the qualitative ORADS score used for diagnosing ovarian cancer. It has shown promise for prediction of resectability (DWI), and to predict and monitor treatment response (radiomics), but these more advanced techniques still need to be matured.

Acknowledgements

No acknowledgement found.

References

No reference found.